Ophthalmology Times Staff

What the approval of a second targeted biologic means for patients, practice, and the evolving TED treatment landscape

The FDA has granted priority review to satralizumab for thyroid eye disease, with a PDUFA date of October 15, 2026, based on phase 3 SatraGO trial data.

Three real-world cases illustrate strategies to identify and manage GA across a range of scenarios, from coexisting wet age-related macular degeneration to functionally monocular patients.

Atsena reported that, since enrollment opened in May 2026, it has already accrued approximately 10% of the pivotal cohort and expects the pace to accelerate as additional sites across North America and Europe are activated.

NCX 470 glaucoma drop gains China regulatory encouragement, clearing path for near-term filings and expanding commercial upside beyond the US.

The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions on leadership development, artificial intelligence, inclusion, and career growth.

A balanced mix of AI-generated and smartphone-captured images eliminated the domain-specific failures seen with single-source training

Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant, a potential first approved treatment for Stargardt disease type 1.

A case report describes image-guided surgical excision combined with adjunctive cryotherapy and a single anterior chamber methotrexate injection, with no recurrence at 10 months.

The update introduces a 250 kHz scan speed for OCT Angiography combined with enhanced TruTrack Active Eye Tracking, as well as new multimodal imaging capabilities, including the Green Autofluorescence Module

The FDA approved the TECNIS PureSee IOL (model ZEN00V) on March 12, 2026.

LENZ Therapeutics licenses FDA-approved presbyopia drop to Everest Medicines for Greater China; NDA under review by NMPA with approval anticipated in Q1 2027

The topical synthetic peptide receives orphan drug and fast track status and enters phase 2 as a first-in-class treatment for a rare degenerative corneal disease.

A pilot study shows that analyzing how the cornea moves under air-puff stimulation may improve early keratoconus detection.

Therini Bio begins a phase 1b DME trial of THN391, an intravitreal antibody targeting fibrin-driven retinal inflammation.

Key regulatory filings, phase 3 readouts, and trial enrollments to watch through June 30.

Phase 2 ArMaDa data show statistically significant 31% reduction in GA lesion growth with OCU410 at 12 months, with a favorable safety profile supporting phase 3 development.

Chiesi Global Rare Diseases said the agency declined to approve its application and requested additional information for the proposed treatment of Leber hereditary optic neuropathy.

ACP says the label “provider” blurs clinical roles, commercializes care, and erodes trust—urging words that protect medical ethics and relationships.

Survey examines experiences and perceptions of patients living with GA.

The National Keratoconus Foundation has named NASCAR driver Joey Gase as Ambassador.

The University of California San Francisco this week debuted the UCSF Wayne and Gladys Valley Center for Vision, bringing its vision care and research facilities under one roof.

The American Medical Association is expressing its support for provisions in proposed Continuing Resolution legislation in Congress that could offer relief to financially strapped physician practices.

Intravitreal injection treats rare autoimmune disease of the central nervous system

Aflibercept (Eylea, Regeneron) has gained FDA approval for treatment of macular edema following CRVO and recommendation for approval by the CHMP for treatment of neovascular AMD.

A phase IIa proof of concept study of a novel rho-kinase (ROCK) inhibitor (AMA0076, Amakem NV) is now underway in patients with glaucoma and ocular hypertension.

QLT Inc. announces that it has completed sale of verteporfin for injection (Visudyne) to Valeant Pharmaceuticals International Inc.

A scientific research grant to cover studies related to dry eye and ocular surface disease will be awarded by CLAO ERF in association with the SSF.

AcuFocus Inc. has received approval from Health Canada to market and sell the Kamra inlay, an innovative corneal inlay to treat presbyopia, within Canada.

The iDesign aberrometer (Abbott) provides an advanced, high-definition measurement device for wavefront-guided LASIK procedures.